
pmid: 32738974
A novel unsymmetrical structural class of orally bioavailable hepatitis C virus (HCV) nonstructural 5A protein (NS5A) inhibitors has been generated by improving both the solubility and membrane permeability of the lead compound found in our previous work. The representative compound 14, with a 5-hydroxymethylpyrazine group and a 3-t-butylpropargyl group on each side of the molecule, exhibited the best oral bioavailability in this study, inhibiting not only the HCV genotype 1a, 1b, 2a, and 3a replicons with EC50 values in the picomolar range, but also inhibited 1a Q30 mutants induced by launched symmetrical inhibitors with EC50 values in the low nanomolar range.
Genotype, Administration, Oral, Hepacivirus, Viral Nonstructural Proteins, Virus Replication, RNA-Dependent RNA Polymerase, Antiviral Agents, Hepatitis C, Structure-Activity Relationship, Pargyline, Pyrazines, Mutation, Humans
Genotype, Administration, Oral, Hepacivirus, Viral Nonstructural Proteins, Virus Replication, RNA-Dependent RNA Polymerase, Antiviral Agents, Hepatitis C, Structure-Activity Relationship, Pargyline, Pyrazines, Mutation, Humans
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
